Endpoint
Knee injury and Osteoarthritis Outcome Score (KOOS)
CAT:outcome/koos-total-scorereported in points (0-100)1 finding from 1 compound
What moved it
How to read these marks1 finding · 1 compound · by evidence strength
| Compound | Direction | Findings | Strongest evidence |
|---|---|---|---|
| resveratrol | up | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
Reported to move it
1 finding
resveratrol — increases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“In Table 2, the administration of resveratrol improves significantly (P < 0.05) both KOOS and WOMAC total scores at the end of the treatment, compared with baseline values and those reported in the control group postintervention.”
Quoted verbatim from Correlation between serum pro inflammatory cytokines and clinical scores of knee osteoarthritic patients using resveratrol as a supplementary therapy with meloxicam.. - Study
- RCT
- Duration
- 3 months
- Dose
- 500 mg/day
- Population
- Adults with painful knee osteoarthritis; resveratrol 500 mg/day plus meloxicam 15 mg/day versus placebo capsule plus meloxicam 15 mg/day (meloxicam in both arms)
Correlation between serum pro inflammatory cytokines and clinical scores of knee osteoarthritic patients using resveratrol as a supplementary therapy with meloxicam.2021PMID:34414904Permalink
How it is measured
Patient-reported knee status on the KOOS instrument, scored 0 to 100 where 100 is no knee problem. The instrument defines five subscales and papers report either the total or individual subscales; which is recorded with each finding, since a subscale is not the total.
Sources cited
1 paper
- Subject
- knee injury and osteoarthritis outcome score (koos)
- Findings
- 1
- Papers
- 1